Clinical Trial Search Results

Filter Results

Age group

Category

Primary purpose

Study type

Location

Search results

You can use the filters to refine your search.

Displaying 1 - 20 of 923

A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SRK-181 ADMINISTERED ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (DRAGON)

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Contact: Kimberly Kelly

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Contact: Rachel Andes
Investigator:
Randolph Hecht

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Kimberly Kelly
Investigator:
Randolph Hecht

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state.

Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Kimberly Kelly
Open Actively Recruiting

Study of Tecovirimat for Human Monkeypox Virus

A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Maricela Gonzalez
Open Actively Recruiting

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Emilie Douine
Open Actively Recruiting

Study of metabolomics and gene expression correlated with myocardial infarction in patients

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Chloe Thorpe
Investigator: Arjun Deb, MD
Open Actively Recruiting

The Impact of Different Urine Collection Techniques to Identify Bacterial And Fungal Species Using Next Generation Sequencing

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Crystal Cisneros
Open Actively Recruiting

A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).

Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts.

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: All
Contact: Rebecca Phelan
Open Actively Recruiting

Phase 2 Study of DKN-01 in Colorectal Cancer

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced CRC patients.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Lisa Yonemoto
Open Actively Recruiting

Mechanical Interventions for Persistent Hypoxemia in Patients Receiving VV ECMO for COVID-19: A Multicenter Retrospective Study

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Jennifer Scovotti
Open Actively Recruiting

Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: KATHRYN B HILBURN
Investigator: Saeed Sadeghi, MD
Open Actively Recruiting

Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.

The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.

Phase: Phase II/III
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Nguyen Do
Open Actively Recruiting

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

This study will assess the safety and efficacy of Posoleucel for the treatment of adenovirus (AdV) infection in pediatric and adult allo-HCT recipients receiving standard of care (SoC).

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Contact: Andres Vargas Gonzalez
Investigator:
Satiro Nakamura De Oliveira

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

Phase: Phase III
Primary Purpose: Treatment
Gender: Male
Age Group: Adults
Contact: Soheila Abbassi
Investigator: John Shen, MD
Open Actively Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Bruck Habtemariam
Open Actively Recruiting

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.

Phase: Phase II/III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Shenetra Walker
Open Actively Recruiting

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib.

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Shenetra Walker
Open Actively Recruiting

A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: KATHRYN B HILBURN
Open Actively Recruiting

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

This is a study to evaluate the safety and efficacy of losmapimod in treating patients with Facioscapulohumeral Muscular Dystrophy (FSHD) over 48 weeks.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Jennifer Huynh